Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of inhaled GB002 for pulmonary arterial hypertension
MOH_2021-05-04_009943Phase 2Not yet recruiting
- Sponsor
- GB002, Inc.
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of seralutinib in pulmonary arterial hypertension (PAH) (2 arms), sponsored by GB002, Inc. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
seralutinib
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2021-05-04_009943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-04_009943.